1. Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity.
- Author
-
Ringel AE, Drijvers JM, Baker GJ, Catozzi A, García-Cañaveras JC, Gassaway BM, Miller BC, Juneja VR, Nguyen TH, Joshi S, Yao CH, Yoon H, Sage PT, LaFleur MW, Trombley JD, Jacobson CA, Maliga Z, Gygi SP, Sorger PK, Rabinowitz JD, Sharpe AH, and Haigis MC
- Subjects
- Adiposity, Animals, CD8-Positive T-Lymphocytes immunology, Cell Line, Tumor, Cell Proliferation, Diet, High-Fat, Fatty Acids metabolism, HEK293 Cells, Humans, Hypoxia-Inducible Factor-Proline Dioxygenases metabolism, Kinetics, Lymphocytes, Tumor-Infiltrating, Mice, Inbred C57BL, Mice, Knockout, Oxidation-Reduction, Principal Component Analysis, Procollagen-Proline Dioxygenase metabolism, Proteomics, Immunity, Neoplasms immunology, Neoplasms metabolism, Obesity metabolism, Tumor Microenvironment
- Abstract
Obesity is a major cancer risk factor, but how differences in systemic metabolism change the tumor microenvironment (TME) and impact anti-tumor immunity is not understood. Here, we demonstrate that high-fat diet (HFD)-induced obesity impairs CD8
+ T cell function in the murine TME, accelerating tumor growth. We generate a single-cell resolution atlas of cellular metabolism in the TME, detailing how it changes with diet-induced obesity. We find that tumor and CD8+ T cells display distinct metabolic adaptations to obesity. Tumor cells increase fat uptake with HFD, whereas tumor-infiltrating CD8+ T cells do not. These differential adaptations lead to altered fatty acid partitioning in HFD tumors, impairing CD8+ T cell infiltration and function. Blocking metabolic reprogramming by tumor cells in obese mice improves anti-tumor immunity. Analysis of human cancers reveals similar transcriptional changes in CD8+ T cell markers, suggesting interventions that exploit metabolism to improve cancer immunotherapy., Competing Interests: Declaration of Interests A.H.S. has patents/pending royalties on intellectual property on the PD-1 pathway from Roche and Novartis. A.H.S. is on advisory boards for Surface Oncology, Elstar, SQZ Biotechnologies, Selecta, Elpiscience, and Monopteros and has research funding from Novartis, Roche, Ipsen, Quark, and Merck. M.C.H. has patents pending on the PHD3 pathway, is on the scientific advisory board for Pori Therapeutics, and has research funding from Roche. J.M.D. has consulted for ElevateBio and Third Rock Ventures. The remaining authors declare no competing interests., (Copyright © 2020. Published by Elsevier Inc.)- Published
- 2020
- Full Text
- View/download PDF